Alzamend Neuro annual ebitda
2022
2023
2024
2025
2026
Alzamend Neuro EBITDA Growth & History (ALZN)
Alzamend Neuro's calculated EBITDA was −$8.7M for fiscal 2026.
View full Alzamend Neuro company overviewAlzamend Neuro annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | −$8.7M | −$4.2M | — |
| 2025 | 2025-04-30 | −$4.4M | $5.4M | — |
| 2024 | 2024-04-30 | −$9.9M | $5.0M | — |
| 2023 | 2023-04-30 | −$14.8M | −$2.5M | — |
| 2022 | 2022-04-30 | −$12.3M | — | — |
Alzamend Neuro quarterly ebitda
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | −$2.8M | −$1.7M | — |
| Q3 2026 | 2026-01-31 | −$2.2M | −$1.1M | — |
| Q2 2026 | 2025-10-31 | −$970,424 | $374,959 | — |
| Q1 2026 | 2025-07-31 | −$2.7M | −$1.7M | — |
| Q4 2025 | 2025-04-30 | −$1.1M | −$288,874 | — |
| Q3 2025 | 2025-01-31 | −$1.0M | $1.6M | — |
| Q2 2025 | 2024-10-31 | −$1.3M | $1.5M | — |
| Q1 2025 | 2024-07-31 | −$949,720 | $2.6M | — |
| Q4 2024 | 2024-04-30 | −$837,377 | $2.5M | — |
| Q3 2024 | 2024-01-31 | −$2.6M | $2.8M | — |
| Q2 2024 | 2023-10-31 | −$2.9M | $212,043 | — |
| Q1 2024 | 2023-07-31 | −$3.5M | −$484,801 | — |
| Q4 2023 | 2023-04-30 | −$3.3M | — | — |
| Q3 2023 | 2023-01-31 | −$5.4M | — | — |
| Q2 2023 | 2022-10-31 | −$3.1M | — | — |
| Q1 2023 | 2022-07-31 | −$3.0M | — | — |
Alzamend Neuro ebitda trends
Across the available reported history, Alzamend Neuro's ebitda decreased from −$4.4M to −$8.7M, a change of −$4.2M. The latest reported quarter, Q4 2026, shows −$2.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alzamend Neuro filings at SEC.gov ↗